Transthyretin Amyloidosis Treatment Market by Drug Type (TTR Stabilizers, Gene Silencing Agents, Enzyme Replacement Therapy, Other Therapeutic Agents), Application (Cardiovascular, Neurological, Renal, Other Organ Involvement), Route of Administration (Oral, Injectable), End-User (Hospitals, Clinics, Homecare), Distribution Channel (Direct Sales, Pharmacies, Online Pharmacies) – Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Transthyretin Amyloidosis Treatment Market was valued at USD 5.1 billion in 2024-e and will surpass USD 10.1 billion by 2030; growing at a CAGR of 10.3% during 2025 - 2030.

The transthyretin amyloidosis (ATTR) treatment market is experiencing rapid growth due to the increasing recognition of ATTR as a rare but debilitating condition with significant impact on patients' quality of life. ATTR is caused by the accumulation of amyloid fibrils, primarily made up of transthyretin (TTR) proteins, in various organs such as the heart, nervous system, and kidneys. The condition can lead to severe organ dysfunction and, if untreated, is often fatal. As awareness of the disease increases, there is a growing focus on developing effective treatments to manage and mitigate the effects of ATTR. This has led to a surge in research and the development of therapies aimed at stabilizing TTR proteins, reducing amyloid deposits, and improving organ function.

The market for ATTR treatment is characterized by a variety of therapeutic options, including TTR stabilizers, gene silencing agents, and enzyme replacement therapy. As the disease can affect multiple organs, treatment options are tailored to address cardiovascular, neurological, and renal complications. With a higher incidence of ATTR among aging populations and patients with underlying genetic predispositions, demand for effective treatments is expected to rise, creating significant opportunities for growth in the market.

TTR Stabilizers Segment Is Largest Owing to Proven Efficacy in Disease Management

The TTR stabilizers segment is the largest in the transthyretin amyloidosis treatment market, primarily due to the proven efficacy of these drugs in slowing disease progression and stabilizing the transthyretin protein. TTR stabilizers, such as tafamidis, work by preventing the dissociation of TTR proteins and the subsequent formation of amyloid fibrils. This mechanism of action helps to reduce the deposition of amyloid in affected organs and alleviate symptoms associated with the disease, particularly in the heart.

TTR stabilizers are considered the standard of care for patients with ATTR, especially those with cardiovascular involvement, as they have demonstrated significant improvements in survival rates and quality of life. The growing clinical evidence supporting the use of TTR stabilizers in various stages of the disease, along with their ability to manage symptoms and slow progression, ensures that this segment remains dominant in the treatment landscape. As new TTR stabilizers continue to be developed and brought to market, the segment is expected to maintain its leading position in the ATTR treatment market.

Neurological Application Segment Is Fastest Growing Due to High Incidence of Neuropathy

The neurological application segment is the fastest growing in the transthyretin amyloidosis treatment market, driven by the high incidence of peripheral neuropathy and autonomic dysfunction associated with ATTR. Neurological involvement in ATTR, particularly in the form of sensorimotor polyneuropathy, is one of the most debilitating aspects of the disease, often leading to progressive loss of motor function, sensory loss, and autonomic dysfunction.

Gene silencing agents, such as patisiran and inotersen, have shown promise in reducing the accumulation of amyloid deposits in the nervous system, leading to significant improvements in symptoms of neurological involvement. As the population affected by neurological symptoms of ATTR continues to grow, the demand for therapies targeting neurological outcomes is expected to increase, making this the fastest growing application segment. Ongoing advancements in gene silencing technologies and their potential to halt or reverse neurological damage further contribute to the rapid expansion of this segment.

Hospitals Segment Is Largest End-User Due to Specialized Care Requirements

The hospitals segment is the largest end-user in the transthyretin amyloidosis treatment market, owing to the complex and specialized care required by ATTR patients. Hospitals are typically equipped with the necessary infrastructure, such as specialized diagnostic tools, advanced imaging technologies, and multidisciplinary care teams, to diagnose and manage ATTR. Given the systemic nature of the disease, which can affect multiple organs, ATTR treatment often requires coordinated care across cardiology, neurology, and nephrology departments, making hospitals the primary setting for treatment.

In addition, hospitals are the focal point for patients requiring intravenous therapies, such as gene silencing agents, and for those undergoing diagnostic procedures like biopsy or genetic testing. As new therapies for ATTR are developed, hospitals are expected to remain the primary end-users, particularly for patients requiring advanced care and management of organ involvement.

Direct Sales Segment Is Fastest Growing Distribution Channel Due to Increased Adoption of Targeted Therapies

The direct sales distribution channel is the fastest growing in the transthyretin amyloidosis treatment market, driven by the increasing adoption of targeted therapies and the need for specialized distribution models. Direct sales allow pharmaceutical companies to maintain closer relationships with healthcare providers, ensuring timely access to the latest treatments and providing comprehensive support services. This distribution model is particularly important for therapies like TTR stabilizers and gene silencing agents, which may require specialized handling, patient education, and ongoing monitoring.

By purchasing directly from manufacturers, healthcare providers can streamline their procurement processes and ensure access to the most effective and up-to-date treatments for ATTR. The growth of personalized medicine, which often involves tailored treatment plans for individuals based on genetic and clinical factors, further fuels the demand for direct sales channels, making this the fastest growing distribution method in the market.

North America Leads the Market Due to High Prevalence and Advanced Healthcare Systems

North America is the largest region in the transthyretin amyloidosis treatment market, largely due to its high prevalence of ATTR, advanced healthcare infrastructure, and early adoption of innovative therapies. The United States and Canada have well-established healthcare systems, with access to cutting-edge treatments and specialized medical centers that focus on rare diseases like ATTR. The availability of FDA-approved therapies, such as tafamidis and patisiran, has further driven the adoption of treatments in this region, positioning North America as a leader in the market.

Additionally, the high awareness of genetic disorders, better access to healthcare services, and ongoing clinical research in North America contribute to the region's dominance. As more treatments become available and the recognition of ATTR as a treatable condition grows, North America is expected to maintain its position as the leading market for ATTR therapies.

Competitive Landscape: Leading Companies Focus on Innovation and Strategic Partnerships

The transthyretin amyloidosis treatment market is competitive, with several pharmaceutical companies leading the charge in developing new therapies. Key players include Pfizer (Tafamidis), Alnylam Pharmaceuticals (Patisiran), and Ionis Pharmaceuticals (Inotersen), which are at the forefront of advancing TTR stabilizers, gene silencing agents, and other therapeutic agents. These companies are heavily investing in research and development to expand treatment options, improve patient outcomes, and address the unmet needs of the ATTR patient population.

In addition to focusing on product innovation, these companies are also forming strategic partnerships with healthcare providers, academic institutions, and other stakeholders to increase awareness of ATTR and improve access to treatments. The competitive landscape is marked by a growing emphasis on personalized therapies, patient support programs, and efforts to expand the market for ATTR treatments globally. As the market continues to evolve, the focus will remain on delivering effective treatments that address the complex nature of this rare disease.

Recent Developments:

• In December 2024, Alnylam Pharmaceuticals received FDA approval for a new gene silencing treatment for transthyretin amyloidosis.
• In November 2024, Pfizer announced a collaboration with Ionis Pharmaceuticals to further develop oral TTR stabilizers for treating amyloidosis.
• In October 2024, Eidos Therapeutics (BridgeBio) presented positive clinical trial results for its oral treatment aimed at improving heart function in transthyretin amyloidosis patients.
• In September 2024, Akcea Therapeutics launched a new injectable treatment for transthyretin amyloidosis with a focus on reducing neurological symptoms.
• In August 2024, Regeneron Pharmaceuticals entered into a research agreement to develop new biologics targeting transthyretin amyloidosis.

List of Leading Companies:

• Alnylam Pharmaceuticals
• Pfizer Inc.
• Ionis Pharmaceuticals
• Teva Pharmaceuticals
• Eidos Therapeutics (Acquired by BridgeBio)
• Bristol Myers Squibb
• Akcea Therapeutics (A Pfizer Company)
• Prothena Corporation
• Regeneron Pharmaceuticals
• Amgen Inc.
• Sanofi
• Intellia Therapeutics
• Dicerna Pharmaceuticals
• Ionis Pharmaceuticals
• Takeda Pharmaceutical Company

Report Scope: